Would you use immune checkpoint inhibitors in patients with well-compensated liver cirrhosis?  

Does the risk of severe inflammation of the liver lead you to choose other therapies in in this population?  What about in patients with mild liver disease, such as early NASH cirrhosis?

Answer from: Medical Oncologist at Academic Institution